Tomita Natsuo, Kodaira Takeshi, Tachibana Hiroyuki, Nakamura Tatsuya, Tomoda Takuya, Nakahara Rie, Inokuchi Haruo, Hayashi Norio, Fuwa Nobukazu
Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Radiother Oncol. 2009 Mar;90(3):346-52. doi: 10.1016/j.radonc.2008.09.020. Epub 2008 Oct 22.
To report the feasibility of dynamic conformal arc radiotherapy with rectum hollow-out technique (DCAT-HO) for localized prostate cancer.
Between October 2000 and April 2007, 204 patients with clinically localized or locally advanced prostate cancer were treated with DCAT-HO. All patients were given neoadjuvant total androgen deprivation (AD) therapy (median 6 months, range 2-27 months). All patients with T3 or T4 stage received post-irradiation AD for 24 months. A total of 128 patients (63%) were treated with 70Gy, and 76 patients (37%) were treated with 74Gy. Acute and late toxicities were scored by the Radiation Therapy Oncology Group morbidity grading scales. PSA relapse was defined as three successive PSA elevations after a post-treatment nadir. The median follow-up was 37 months.
Both the acute Grade 2 rectal and urinary toxicities were 1.0%, and no patients experienced acute Grade 3 or higher symptoms. The 3-year rates of both late Grade 2 rectal and urinary toxicities were 3.4%. The 3-year PSA relapse-free survival for low, intermediate, and high-risk group patients treated with 70 Gy were 54%, 75%, and 87%, respectively.
These findings demonstrate the feasibility of DCAT-HO in a large number of patients with short follow-up. DCAT-HO reduced the volume of the rectum exposed to higher doses and this led to an overall reduction in late rectal toxicity.
报告采用直肠中空技术的动态适形弧形放疗(DCAT-HO)治疗局限性前列腺癌的可行性。
2000年10月至2007年4月,204例临床局限性或局部晚期前列腺癌患者接受了DCAT-HO治疗。所有患者均接受新辅助全雄激素剥夺(AD)治疗(中位时间6个月,范围2 - 27个月)。所有T3或T4期患者放疗后接受24个月的AD治疗。128例患者(63%)接受70Gy治疗,76例患者(37%)接受74Gy治疗。急性和晚期毒性反应根据放射肿瘤学组的发病率分级量表进行评分。PSA复发定义为治疗后最低点后连续三次PSA升高。中位随访时间为37个月。
急性2级直肠和泌尿系统毒性反应均为1.0%,无患者出现急性3级或更高等级症状。晚期2级直肠和泌尿系统毒性反应的3年发生率均为3.4%。接受70Gy治疗的低、中、高危组患者的3年无PSA复发生存率分别为54%、75%和87%。
这些结果表明DCAT-HO在大量短期随访患者中的可行性。DCAT-HO减少了直肠接受高剂量照射的体积,从而总体上降低了晚期直肠毒性。